When new safety information for medicines is identified, the Therapeutic Goods Administration (TGA) works with the sponsors to update Product Information (PI) to ensure that health professionals and consumers have access to this information. New safety information can be identified through the TGA’s ongoing safety monitoring activities or uncovered and submitted by sponsors themselves. Please see below details of some medicines that have recently had safety related updates to their PI.
The TGA monitors the safety of medicines marketed in Australia using:
- reports of adverse events
- Risk Management Plans (RMPs) and Periodic Safety Update Reports (PSURs)
- reviews of literature
- sharing of information with other regulatory agencies
- sharing of information with Australian state and territory health authorities.
Changes to the PI that result from TGA safety monitoring activities may:
- narrow indications
- add or modify specific sections, such as:
- contraindications
- warnings or precautions
- use in fertility, pregnancy and lactation
- use in special populations
- adverse effects.
It is important for prescribers and other health professionals to be aware of safety-related PI changes, as they may require you to take actions or do things differently, such as:
- counsel patients on identified risks
- undertake special monitoring or precautions
- in some instances select alternate medications.
Significant PI changes are often supported by distribution of a Dear Health Care Professional Letter on the issue, which are produced by the medicine’s sponsor and sent directly to health professionals.
We will publish a Medicines Safety Update (MSU) article detailing recent safety-related PI updates each month, although this may not include all safety-related updates. We will continue to publish MSU articles for critical safety issues or topics of special interest.
The below medicines are generally innovator brands (generic brands may be included in some circumstances). Generic brands containing the same active ingredients as the medicines below are required to align with the safety information in the innovator’s PI and will be updated accordingly.
To view the full PI for each listing, click on the name of the product in the ‘Brand/trade name’ column. A ‘Summary table of changes’ appears at the end of the PI. If the TGA has published any further risk communication, such as a safety alert or stand-alone MSU article, it will be linked to in the ‘Safety issue’ column.
| Active ingredients | Brand Name Sponsor | PI updates (sections updated and summary of key information) | Date of approval |
|---|---|---|---|
alendronate sodium colecalciferol | Organon Pharma Pty Ltd | 4.4 – Special warnings and precautions for use
| 26 May 2023 |
atezolizumab | Roche Products Pty Ltd | 4.4 – Special warnings and precautions for use
4.8 – Adverse effects (undesirable effects)
| 29 June 2023 |
azithromycin dihydrate | Pfizer Australia Pty Ltd | 4.2 – Dose and method of administration 4.4 – Special warnings and precautions for use 5.2 – Pharmacokinetic properties
4.6 – Fertility, pregnancy and lactation
| 19 June 2023 |
carbamazepine | Novartis Pharmaceuticals Australia Pty Ltd | 4.4 – Special warnings and precautions for use
4.5 – Interactions with other medicines and other forms of interactions
4.6 – Fertility, pregnancy and lactation
| 6 June 2023 |
fentanyl | Janssen-Cilag Pty Ltd | 4.9 – Overdose
| 6 June 2023 |
flucloxacillin (as sodium) | Aspen Pharmacare Australia Pty Ltd | 4.4 – Special warnings and precautions for use
4.8 – Adverse effects (undesirable effects)
| 23 June 2023 |
fluticasone furoate | GlaxoSmithKline Australia Pty Ltd | 4.8 – Adverse effects (undesirable effects)
| 15 June 2023 |
fluticasone furoate/ umeclidinium (as bromide)/ vilanterol (as trifenatate) | GlaxoSmithKline Australia Pty Ltd | 4.8 – Adverse effects (undesirable effects)
| 14 June 2023 |
guanfacine (as hydrochloride) | Takeda Pharmaceuticals Australia Pty Ltd | 4.8 – Adverse effects (undesirable effects)
| 26 June 2023 |
lanreotide acetate | Ipsen Pty Ltd | 4.4 – Special warnings and precautions for use
4.8 – Adverse effects (undesirable effects)
| 1 June 2023 |
mesalazine | Chiesi Australia Pty Ltd | 4.4 – Special warnings and precautions for use
4.8 – Adverse effects (undesirable effects)
| 27 June 2023 |
methylphenidate hydrochloride | Janssen-Cilag Pty Ltd | 4.8 – Adverse effects (undesirable effects)
| 15 June 2023 |
naltrexone hydrochloride plus bupropion hydrochloride | iNova Pharmaceticals (Australia) Pty Ltd | 4.4 – Special warnings and precautions for use
| 29 June 2023 |
naproxen sodium | Atnahs Pharma Australia Pty Ltd | 4.3 – Contraindications
4.6 – Fertility, pregnancy and lactation
| 2 June 2023 |
nexviazyme | Sanofi-Aventis Australia Pty Ltd | 4.8 – Adverse effects (undesirable effects)
| 22 June 2023 |
olanzapine | Eli Lilly Australia Pty Ltd | 4.8 – Adverse effects (undesirable effects)
| 21 June 2023 |
olanzapine pamoate monohydrate | Eli Lilly Australia Pty Ltd | 4.8 – Adverse effects (undesirable effects)
| 21 June 2023 |
omeprazole (as magnesium) | Pharmaco Australia Ltd | 4.4 – Special warnings and precautions for use
4.8 – Adverse effects (undesirable effects)
| 22 June 2023 |
oxycodone hydrochloride plus naloxone hydrochloride dihydrate | Mundipharma Pty Ltd | 4.2 – Dose and method of administration 4.4 – Special warnings and precautions for use
4.8 – Adverse effects (undesirable effects)
4.9 – Overdose
| 27 June 2023 |
paliperidone palmitate | Janssen-Cilag Pty Ltd | 4.2 – Dose and method of administration
| 8 June 2023 |
paracetamol and ibuprofen sodium dihydrate | AFT Pharmaceuticals Pty Ltd | 4.4 – Special warnings and precautions for use 4.8 – Adverse effects (undesirable effects)
| 26 June 2023 |
remdesivir | Gilead Sciences Pty Ltd | 4.4 – Special warnings and precautions for use
| 29 June 2023 |
trimethoprim/ sulfamethoxazole | Arrotex Pharmaceuticals Pty Ltd | 4.4 – Special warnings and precautions for use
| 31 May 2023 |
umeclidinium (as bromide)/ vilanterol (as trifenatate) | GlaxoSmithKline Australia Pty Ltd | 4.8 – Adverse effects (undesirable effects)
| 31 May 2023 |
umeclidinium bromide | GlaxoSmithKline Australia Pty Ltd | 4.8 – Adverse effects (undesirable effects)
| 16 June 2023 |
Disclaimer
Medicines Safety Update is aimed at health professionals. It is intended to provide practical information to health professionals on medicine safety, including emerging safety issues. The information in Medicines Safety Update is necessarily general and is not intended to be a substitute for a health professional’s judgment in each case, taking into account the individual circumstances of their patients. Reasonable care has been taken to ensure that the information is accurate and complete at the time of publication. The Australian Government gives no warranty that the information in this document is accurate or complete, and shall not be liable for any loss whatsoever due to negligence or otherwise arising from the use of or reliance on this document.
© Commonwealth of Australia 2023
This work is copyright. You may reproduce the whole or part of this work in unaltered form for your own personal use or, if you are part of an organisation, for internal use within your organisation, but only if you or your organisation do not use the reproduction for any commercial purpose and retain this copyright notice and all disclaimer notices as part of that reproduction. Apart from rights to use as permitted by the Copyright Act 1968 or allowed by this copyright notice, all other rights are reserved and you are not allowed to reproduce the whole or any part of this work in any way (electronic or otherwise) without first being given specific written permission from the Commonwealth to do so. Requests and inquiries concerning reproduction and rights are to be sent to the TGA Copyright Officer, Therapeutic Goods Administration, PO Box 100, Woden ACT 2606 or emailed to [email protected].
For the latest safety information from the TGA, subscribe to the TGA Safety Information email list via the TGA website.
For correspondence or further information about Medicines Safety Update, contact the TGA’s Pharmacovigilance Branch at [email protected].
